- Report
- March 2025
- 185 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- October 2024
- 318 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- May 2018
- 204 Pages
Global
From €2138EUR$2,349USD£1,833GBP
- Report
- June 2018
- 15 Pages
Global
From €9101EUR$10,000USD£7,802GBP
- Book
- October 2024
Global
The ND0612 market is a segment of the Central Nervous System (CNS) Drugs market. It includes drugs used to treat a variety of neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, depression, anxiety, and schizophrenia. These drugs are typically prescribed by psychiatrists, neurologists, and other healthcare professionals. The ND0612 market is highly competitive, with a wide range of products available from both generic and branded manufacturers.
The ND0612 market is also characterized by a high degree of innovation, with new drugs and treatments being developed to address unmet medical needs. Many of these drugs are developed through collaborations between pharmaceutical companies and academic institutions.
Some of the major companies in the ND0612 market include Pfizer, Eli Lilly, Johnson & Johnson, Merck, and Novartis. Other companies include AstraZeneca, GlaxoSmithKline, Sanofi, and Teva Pharmaceuticals. Show Less Read more
